SELEGILINE HYDROCHLORIDE (selegiline hydrochloride) by Molecular Devices is clinical pharmacology the mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of parkinson's disease are not fully understood. First approved in 1996.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of Parkinson's disease are not fully understood. Inhibition of monoamine oxidase, type B, activity is generally considered to be of primary importance; in addition, there is evidence that…
Worked on SELEGILINE HYDROCHLORIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.